In:
Journal of Viral Hepatitis, Wiley, Vol. 26, No. 1 ( 2019-01), p. 118-125
Abstract:
In this open‐label study in patients with genotype D, HB eAg‐negative chronic hepatitis B receiving nucleos(t)ide analogue therapy and with HBV DNA 〈 20 IU/mL, peginterferon alfa‐2a add‐on therapy reduced HB sAg levels, with 29/43 (67.4%) patients having a 〉 50% decline in HB sAg at week 48. An increase in Interferon gamma‐induced protein 10 from baseline up to week 48 was significantly associated with response. image
Type of Medium:
Online Resource
ISSN:
1352-0504
,
1365-2893
DOI:
10.1111/jvh.2019.26.issue-1
Language:
English
Publisher:
Wiley
Publication Date:
2019
detail.hit.zdb_id:
2007924-2
Permalink